(Reporter Zhang Min) On November 20, Innovent Biologics Inc. (hereinafter referred to as " Innovent Biologics "), a Hong Kong-listed company, announced that its independently developed GCG/GLP-1 dual receptor agonist, Mastodide, the world's first such drug, has met its primary endpoint and all key secondary endpoints in the Phase III clinical trial GLORY-2 in Chinese patients with moderate to severe obesity (BMI ≥ 30 kg/m²).
Currently, obesity prevalence is high in my country, and the "large body weight" group (BMI exceeding 30 kg/m²) often bears a greater burden of cardiovascular and metabolic diseases, making them a patient group that requires special attention in clinical weight management and prevention of metabolic syndrome. Effective drug treatment options are currently lacking for this population. In the GLORY-2 study, the participants' baseline average BMI exceeded 34 kg/m², which falls into the category of moderate to severe obesity in my country.
Professor Ji Linong of Peking University People's Hospital, the lead investigator of GLORY-2, stated: "As a chronic disease, obesity prevention and treatment require high attention from the entire society. my country has a high prevalence of obesity, and obese individuals often bear a heavy burden of cardiovascular and metabolic diseases. They are a patient group that requires special attention in clinical weight management and the prevention and treatment of metabolic syndrome. According to current clinical guidelines in my country, metabolic surgery is often the first-line treatment for these patients. Extensive clinical evidence shows that the weight loss effect of GLP-1 receptor agonists is positively correlated with dosage. Therefore, developing drug treatments suitable for moderate to severe obesity will provide new treatment options for this population."
According to Innovent Biologics , the study enrolled 462 participants, including those with simple obesity and obesity combined with diabetes, and randomly assigned them in a 2:1 ratio to either the masuropein 9mg group or the placebo group. The treatment was double-blind for 60 weeks. Results from the GLORY-2 study showed that, compared to placebo, the masuropein 9mg group achieved significant weight loss, as well as significant reductions in waist circumference, systolic blood pressure, triglycerides, non-HDL cholesterol, LDL cholesterol, and uric acid.
Currently, the approved dosage strengths of Mastodextrin are 2mg, 4mg and 6mg, mainly for people with BMI ≥ 28kg/m² or 24kg/m² ≤ BMI < 28kg/m² and accompanied by at least one obesity-related complication.
Dr. Qian Lei, Chief Research Officer of Innovent Biologics' Integrated Pipeline, pointed out: "The development of Mastodipeptide 9mg is aimed at the weight loss needs of Chinese patients with a BMI greater than 30kg/m², especially those with a BMI of 32.5kg/m² or higher who are moderately to severely obese. In the past, this group of people could only achieve effective weight management through bariatric surgery."
Innovent Biologics plans to submit a marketing application to the National Medical Products Administration (NMPA) for masidopeptide 9mg for adult weight management. Qian Lei stated, "The lifecycle management plan surrounding masidopeptide continues to expand its boundaries, and we will continue to promote the development of more indications for masidopeptide based on scientific evidence and unmet medical needs."

https://finance.eastmoney.com/a/202511203570182619.html